<DOC>
	<DOCNO>NCT01654575</DOCNO>
	<brief_summary>Osteoarthritis ( OA ) common disable condition , effective therapy currently exists.Synovitis commonly demonstrate knee OA imaging . Methotrexate ( MTX ) help decrease synovitis many inflammatory joint disease , particularly rheumatoid arthritis.Accordingly , aim present study ass efficacy MTX decrease pain inflammation.Eighty-eight patient clinical radiographic criterion primary knee OA knee pain , include study.Patients meet eligibility criterion randomize 1:1 ratio receive either 25mg/week oral MTX ( n=44 ) placebo ( n=44 ) 16 week . The primary outcome measure pain reduction secondary outcome measure include improvement physical function scores.There statistically significant reduction pain improvement function MTX group compare placebo group 16 week .</brief_summary>
	<brief_title>Methotrexate Symptomatic Knee Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>primary knee osteoarthritis pain respond usual therapy synovitis inflammatory condition , hepatic renal insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Knee Osteoarthritis</keyword>
	<keyword>Synovitis</keyword>
	<keyword>Pain reduction</keyword>
	<keyword>Function score</keyword>
</DOC>